Using Nigeria as a case study
The African healthcare system operates under persistent and immense financial strain. Primary health centres struggle with limited capitation, lack of government funding and out-of-pocket dependence, secondary hospitals face rising operating costs and workforce attrition, while tertiary and teaching hospitals balance service delivery with heavy academic and referral burdens and a drained specialist workforce
Within this context, an important strategic question is emerging among African clinicians, medical directors, and hospital owners: How can we improve revenue, can clinical research function as a commercially viable business line for African healthcare institutions without undermining patient care, and can it add additional strain to an already stretched workforce? Well, I am here to tell you the answer is YES but only when clinical research is treated as a structured business operation, not an informal academic add-on.
Clinical research in Africa: from a historic academic exercise to revenue stream
In practical terms, clinical research is a paid service. Pharmaceutical sponsors, biotechnology companies, and Contract Research Organisations (CROs) fund sites to deliver clearly defined outputs per the Clinical Trial Agreement (CTA):
- Identification, screening, and enrolment of eligible patients
- Protocol-driven clinical assessments and follow-up
- Source documentation and data capture
- Safety reporting and pharmacovigilance
- Compliance with regulatory and ethics requirements
In return, African sites receive:
- Study start-up fees
- Per-patient recruitment and visit payments
- Monitoring visit fees
- Pharmacy, laboratory, and overhead recoveries
When properly negotiated and efficiently delivered, these payments can generate predictable, recurring income.
Where African healthcare (specifically Nigeria) tiers fit commercially
Primary care facilities: Familiarity with patient and readily available patient cohort as a commercial asset
Nigeria’s primary care ecosystem, including private clinics, HMOs’ provider networks, and community health centres controls the country’s largest patient access funnel. These facilities are commercially well-suited for:
- Feasibility and epidemiological studies
- Vaccine trials
- Hypertension, diabetes, asthma, and infectious disease studies
Post-marketing and real-world evidence research
From a business perspective, primary care research is volume-driven and operationally lean. Infrastructure requirements are modest, but success depends on workflow discipline, staff training, and data quality. For many Nigerian clinics, research income can meaningfully supplement consultation fees and improve staff retention.
Secondary hospitals: Nigeria’s research profitability “sweet spot”
Secondary hospitals; both public and private often represent the most commercially balanced research environment in Nigeria. They combine:
- Defined catchment populations
- Diagnostic and inpatient capability
- Moderate governance complexity
These institutions are ideal for Phase II–IV interventional studies, device trials, and post-approval safety studies. Financially, they can achieve strong margins by layering research activity onto existing clinical services with minimal incremental overhead.
For many Nigerian hospitals, clinical research revenue has been used to:
- Fund staff incentive schemes
- Upgrade consultation, diagnostics and pharmacy infrastructure through capacity building.
- Stabilise cash flow during low patient-volume periods
Tertiary and teaching hospitals: high-value, high-cost research engines
Nigeria’s teaching hospitals and federal medical centres are natural anchors for advanced research, including:
- Oncology and rare disease trials
- Complex infectious disease programmes
- Biomarker-driven and early-phase studies
These trials attract higher per-patient payments but also carry high fixed costs specialist investigators, research pharmacists, advanced laboratories, imaging, and governance oversight.
Commercial sustainability at this level depends on portfolio strategy: blending high-complexity trials with larger late-phase studies to smooth cash flow and optimise staff utilisation.
The real economics of clinical research in Nigeria
Clinical research is not automatically profitable in Nigeria. Sites fail when they underestimate the business fundamentals:
- Feasibility realism: Overpromising recruitment damages sponsor confidence and site finances.
- Cost transparency: Many sites underprice staff time, overheads, and inflationary pressures.
- Contract discipline: Weak budget negotiation and delayed payments erode margins.
- Operational maturity: Poor documentation and protocol deviations increase rework and audit risk.
- Pipeline thinking: One-off trials rarely justify investment—repeat business does.
- Operational and logistical challenges: Lack of infrastructure I.e electricity instability, poor road access
Successful Nigerian sites treat research as a profit-and-loss unit, with governance, forecasting, and performance metrics.
Why many Nigerian facilities struggle and why that is changing
Historically, Nigerian healthcare institutions have struggled with clinical research because they:
- Engage reactively rather than strategically
- Lack dedicated research management structures
- Rely on individual investigators instead of institutional systems
- Underestimate regulatory and sponsor expectations
However, global sponsors are actively diversifying trial geographies, and Nigeria’s large, treatment-naïve patient populations are increasingly attractive. Facilities that professionalise their approach are now competing effectively with sites in Eastern Europe, Latin America, and parts of Asia.
Strategic value beyond direct revenue
For Nigerian healthcare institutions, the business case for clinical research extends beyond cash flow:
- Improved clinical governance and protocol discipline
- Continuous professional development for doctors and nurses
- Earlier patient access to innovative therapies
- Enhanced institutional credibility with regulators and partners
- Stronger positioning for international collaborations and grants
In many cases, these strategic benefits compound over time, strengthening the core healthcare business.
Clinical research can be a viable and sustainable business for Nigerian primary, secondary, and tertiary care units but only when it is approached with commercial clarity and operational discipline.
This is where Biopharmaal Consulting partners with healthcare providers.
Biopharmaal Consulting supports hospitals and clinics to:
- Assess research readiness and commercial viability
- Design fit-for-purpose research operating models aligned to its country realities
- Identify the right trial types for each level of care
- Navigate NAFDAC, NHREC, and institutional ethics processes
- Negotiate commercially sound budgets and payment terms
- Transition from opportunistic studies to sustainable clinical research pipelines
If you are a clinician, medical director, hospital owner, or health system leader in Nigeria considering clinical research not as a side activity, but as a strategic business line, the conversation should start now.
Done right, clinical research does not distract Nigerian healthcare institutions from care delivery.
It strengthens them clinically, reputationally, and financially.